MedicaidPrior AuthMedium impact
Columvi™ (glofitamab-gxbm) (New)
Humana·IN · Oncology, Hematology·Medicaid
Effective date
May 1, 2026
We identified it
Jun 24, 2026
Summary
New prior authorization policy for Columvi (glofitamab-gxbm), a cancer drug for relapsed/refractory large B-cell lymphoma, effective May 1, 2026 for Indiana Medicaid patients. Prior auth required with specific criteria including diagnosis confirmation, two prior treatment lines, and monotherapy use.
Action Required
Before May 1, 2026: Billing team must implement prior authorization requirements for Columvi (glofitamab-gxbm) for Indiana Medicaid patients. Update billing system to flag this drug for prior auth. Providers must verify patients meet all three criteria: DLBCL/LBCL diagnosis, two prior treatment lines, and monotherapy use. Visit www.humana.com/PAL for medical coding information. Claims without prior auth will be denied.